MTAP and cancer: Additionally, TNG462 was assessed in the same 7-day viability assay usinga 179-cancer cell line panel representing multiple lineages and showedan median 41-fold selectivity for MTAP-null cell lines relative toMTAP WT cell lines (Figure 9).